Tetra Bio-Pharma Inc. (TSXV:TBP), a Canadian biopharma stock, climbed after signing a co-development and commercialization agreement with Alternavida S.A. de C.V.
A cannabinoid-based pain drug development deal lifted a Canadian biopharma stock Monday. Here’s some small stocks making big moves on Monday, December 2, 2019 (as of 4 pm EST):
Tetra Bio-Pharma Inc. (TSXV:TBP), a Canadian biopharma stock, powered 35% higher to $0.50 on Monday after announcing that it has signed a definitive co-development and commercialization agreement with Alternavida S.A. de C.V. for the clinical development, marketing and distribution of CAUMZ, a cannabinoid-derived therapeutic composed of pure synthetic THC and CBD for use in treatment of chronic pain, in Mexico. Tetra will receive a one-time license fee of C$125,000 as well as royalties on CAUMZ sales in Mexico of 10% in year one, 12.5% in year two, and 15% in years three to 15.
As well, shares of Centerra Gold Inc. (TSX:CG) slipped 11% to $10.06 as the gold miner said two of its employees are missing following what it called a “significant rock movement” at its Kumtor Mine in the Kyrgyz Republic.
Continental Gold Inc. (TSX:CNL), meanwhile, reported that it has agreed to be acquired by Zijin Mining Group Co., Ltd. at a price of C$5.50 per share in cash, or a total consideration of approximately C$1.4 billion on a fully-diluted basis. Continental Gold stock moved up 11% to $5.39 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Tetra Bio-Pharma Inc. (TSXV:TBP), a Canadian biopharma stock, powered 35% higher to $0.50 on Monday after announcing that it has signed a definitive co-development and commercialization agreement with Alternavida S.A. de C.V. for the clinical development, marketing and distribution of CAUMZ, a cannabinoid-derived therapeutic composed of pure synthetic THC and CBD for use in treatment of chronic pain, in Mexico. Tetra will receive a one-time license fee of C$125,000 as well as royalties on CAUMZ sales in Mexico of 10% in year one, 12.5% in year two, and 15% in years three to 15.
